Oct 19, 2026 08:00AM
Oct 9, 2026 08:00AM
Oct 9, 2026 08:00AM
Sep 24, 2026 08:01AM
Sep 24, 2026 08:00AM
Aug 27, 2026 08:01AM
Aug 27, 2026 08:00AM Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
Aug 21, 2026 08:00AM
Aug 21, 2026 08:00AM
Aug 20, 2026 06:55AM
Aug 12, 2026 07:08AM
Aug 4, 2026 04:01PM
Jul 2, 2026 09:30PM
May 14, 2026 08:30AM Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 13, 2026 07:11AM
May 6, 2026 08:00AM
Apr 10, 2026 08:01AM
Apr 10, 2026 08:00AM
Apr 7, 2026 08:30AM
Apr 2, 2026 08:00AM
Mar 31, 2026 08:00AM Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies
Mar 16, 2026 08:13AM
Mar 12, 2026 08:00AM
Feb 26, 2026 08:00AM
Feb 10, 2026 08:03AM
Feb 10, 2026 08:00AM
Feb 3, 2026 08:00AM
Jan 26, 2026 08:02AM Milestone's CARDAMYST nasal spray now available at U.S. pharmacies
Jan 26, 2026 08:00AM
Jan 13, 2026 06:09AM
Jan 6, 2026 08:02AM
Jan 6, 2026 08:00AM
Dec 21, 2025 04:00AM
Dec 17, 2025 05:00PM
Dec 17, 2025 05:00PM Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)
Dec 15, 2025 10:03AM
Dec 12, 2025 08:00PM
Dec 12, 2025 08:00PM
Nov 12, 2025 07:01AM
Nov 4, 2025 04:05PM
Nov 3, 2025 08:00AM
Oct 9, 2025 08:00AM Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
Aug 19, 2025 08:00AM
Aug 12, 2025 07:05AM
Jul 11, 2025 09:32AM
Jul 11, 2025 09:30AM
Jul 11, 2025 06:02AM
Jul 11, 2025 06:01AM
Jul 11, 2025 06:00AM Milestone Pharmaceuticals receives FDA acceptance for CARDAMYST response
Jul 11, 2025 06:00AM

335,228 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All